Teva Pharmaceutical Statistics

Total Valuation

Teva Pharmaceutical has a market cap or net worth of $32.65 billion. The enterprise value is $47.54 billion.

Market Cap	32.65B
Enterprise Value	47.54B

Important Dates

The last earnings date was Wednesday, November 5, 2025, before market open.

Earnings Date	Nov 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 2.33% in one year.

Current Share Class	n/a
Shares Outstanding	1.15B
Shares Change (YoY)	+2.33%
Shares Change (QoQ)	+0.26%
Owned by Insiders (%)	0.41%
Owned by Institutions (%)	71.88%
Float	1.14B

Valuation Ratios

The trailing PE ratio is 46.12 and the forward PE ratio is 11.16. Teva Pharmaceutical's PEG ratio is 1.74.

PE Ratio	46.12
Forward PE	11.16
PS Ratio	1.94
Forward PS	1.88
PB Ratio	4.50
P/TBV Ratio	n/a
P/FCF Ratio	56.49
P/OCF Ratio	30.63
PEG Ratio	1.74

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.40, with an EV/FCF ratio of 82.25.

EV / Earnings	66.68
EV / Sales	2.83
EV / EBITDA	10.40
EV / EBIT	13.35
EV / FCF	82.25

Financial Position

The company has a current ratio of 1.11, with a Debt / Equity ratio of 2.36.

Current Ratio	1.11
Quick Ratio	0.52
Debt / Equity	2.36
Debt / EBITDA	3.62
Debt / FCF	29.57
Interest Coverage	3.73

Financial Efficiency

Return on equity (ROE) is 9.71% and return on invested capital (ROIC) is 8.90%.

Return on Equity (ROE)	9.71%
Return on Assets (ROA)	5.45%
Return on Invested Capital (ROIC)	8.90%
Return on Capital Employed (ROCE)	12.55%
Revenue Per Employee	$455,498
Profits Per Employee	$19,359
Employee Count	36,830
Asset Turnover	0.41
Inventory Turnover	2.30

Taxes

In the past 12 months, Teva Pharmaceutical has paid $238.00 million in taxes.

Income Tax	238.00M
Effective Tax Rate	26.44%

Stock Price Statistics

The stock price has increased by +59.89% in the last 52 weeks. The beta is 0.67, so Teva Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	+59.89%
50-Day Moving Average	22.33
200-Day Moving Average	18.08
Relative Strength Index (RSI)	80.34
Average Volume (20 Days)	11,400,738

Short Selling Information

Short Interest	46.44M
Short Previous Month	47.28M
Short % of Shares Out	4.07%
Short % of Float	n/a
Short Ratio (days to cover)	3.67

Income Statement

In the last 12 months, Teva Pharmaceutical had revenue of $16.78 billion and earned $713.00 million in profits. Earnings per share was $0.62.

Revenue	16.78B
Gross Profit	8.40B
Operating Income	3.56B
Pretax Income	900.00M
Net Income	713.00M
EBITDA	4.57B
EBIT	3.56B
Earnings Per Share (EPS)	$0.62

Full Income Statement

Balance Sheet

The company has $2.20 billion in cash and $17.09 billion in debt, giving a net cash position of -$14.89 billion or -$12.98 per share.

Cash & Cash Equivalents	2.20B
Total Debt	17.09B
Net Cash	-14.89B
Net Cash Per Share	-$12.98
Equity (Book Value)	7.25B
Book Value Per Share	6.32
Working Capital	1.25B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $1.07 billion and capital expenditures -$488.00 million, giving a free cash flow of $578.00 million.

Operating Cash Flow	1.07B
Capital Expenditures	-488.00M
Free Cash Flow	578.00M
FCF Per Share	$0.50

Full Cash Flow Statement

Margins

Gross margin is 50.09%, with operating and profit margins of 21.22% and 4.25%.

Gross Margin	50.09%
Operating Margin	21.22%
Pretax Margin	5.36%
Profit Margin	4.25%
EBITDA Margin	27.25%
EBIT Margin	21.22%
FCF Margin	3.45%

Dividends & Yields

Teva Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.33%
Shareholder Yield	-2.33%
Earnings Yield	2.18%
FCF Yield	1.77%

Dividend Details

Analyst Forecast

The average price target for Teva Pharmaceutical is $27.00, which is -5.13% lower than the current price. The consensus rating is "Strong Buy".

Price Target	$27.00
Price Target Difference	-5.13%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.

Last Split Date	Jul 1, 2004
Split Type	Forward
Split Ratio	2:1

Scores

Teva Pharmaceutical has an Altman Z-Score of 0.62 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.62
Piotroski F-Score	7